In carnosine-treated cells, differentiation and phenotype are altered, increasing expression of CD11b, CD11c, CD86, and MHCII, thus enabling the promonocytic leukemia cells to be more visible to the immune system. The gene discussed is ITGAX; the disease is leukemia.